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Prostate cancer is the most frequently diagnosed male cancer, and its clinical outcome is difficult to predict. The disease may involve
the inappropriate expression of genes that normally control the proliferation of epithelial cells in the basal layer and their
differentiation into luminal cells. Our aim was to identify novel basal cell markers and assess their prognostic and functional significance
in prostate cancer. RNA from basal and luminal cells isolated from benign tissue by immunoguided laser-capture microdissection was
subjected to expression profiling. We identified 112 and 267 genes defining basal and luminal populations, respectively. The
transcription factor TEAD1 and the ubiquitin ligase c-Cbl were identified as novel basal cell markers. Knockdown of either marker
using siRNA in prostate cell lines led to decreased cell growth in PC3 and disrupted acinar formation in a 3D culture system of
RWPE1. Analyses of prostate cancer tissue microarray staining established that increased protein levels of either marker were
associated with decreased patient survival independent of other clinicopathological metrics. These data are consistent with basal
features impacting on the development and clinical course of prostate cancers.
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Prostate cancer is one of the most common malignancies in the
western world, but markers that accurately predict the highly
variable course of the disease are lacking.
Normal prostate tissue consists of glands containing two well-
defined epithelial layers surrounding a central lumen. The outer basal
layer is the site of proliferation (Hudson et al, 2001) and the inner layer
is made up of secretory luminal cells arising from the basal layer
through differentiation (Signoretti et al,2 0 0 5 ) .C h a n g e si nt h eb a l a n c e
between epithelial cell division and differentiation may play a key role
in the development of both prostate cancer and benign prostatic
hyperplasia (BPH) (Bonkhoff and Remberger, 1996). Prostate cancer
cells resemble those of the luminal layer (Browne et al, 2004),
particularly in their expression of prostate-specific antigen (PSA) and
the androgen receptor (AR). Unlike luminal cells, however, and in
common with basal cells, cancer cells maintain the ability to
proliferate. Although a defining feature of prostate cancer is the
complete loss of the basal cell layer, there is evidence for a maintained
expression of genes normally restricted to basal cells, including MET
(Pisters et al, 1995), BCL-2 (McDonnell et al, 1992), SOX9 (Wang et al,
2007), KLK4 (Klokk et al, 2007) and S100A9 (Hermani et al, 2005).
Furthermore, the cancer-initiating cell is widely believed to be of basal
origin (Bui and Reiter, 1998), expressing known basal markers
including keratin (K)14, a2b1 integrin and CD44 (Collins et al, 2005;
Patrawala et al, 2007). We therefore hypothesised that basal cell
features are of key importance in the development of prostate tumours.
To address this, we used immunoguided laser-capture micro-
dissection to isolate prostate basal and luminal epithelial cells
under conditions that preserve RNA of sufficient quality for
expression profiling. This identified gene expression patterns
relating to proliferation and differentiation within benign prostate
epithelium. TEAD1 (a transcription factor) and c-Cbl (an E3
ubiquitin ligase) were confirmed as novel basal cell markers.
Analysis of their expression across a range of prostate cancer
samples on tissue microarrays (TMAs) demonstrated each to have
a prognostic value. Finally, the functional significance of TEAD1
and c-Cbl in controlling growth and differentiation of prostate cell
lines was examined using RNA interference.
MATERIALS AND METHODS
Clinical material
Frozen tissue was obtained from five consented patients under-
going transurethral resection of the prostate for BPH.
The TMA consisted of 774 formalin-fixed paraffin-embedded
cores representing benign epithelium (43 patients), hyperplastic
Received 31 July 2008; revised 16 October 2008; accepted 16 October
2008; published online 11 November 2008
*Correspondence: Dr DL Hudson; E-mail: dh560@york.ac.uk
British Journal of Cancer (2008) 99, 1849–1858
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sepithelium (124 patients) and prostate cancer (147 patients)
(Foster et al, 2004). The prostate cancer samples were from
consecutive patients attending the Royal Marsden NHS Trust from
1992 with follow-up times of up to 16.6 years (median 6.9 years).
Owing to the long follow-up period for this patient set, PSA values
were unavailable for many patients.
Immunohistochemistry and laser microdissection pressure
catapulting
Basal cells were distinguished by immunostaining for K14 (Abd
Serotec, Kidlington, UK). Primary and secondary antibodies were
used at 1:25 and 1:100 dilutions, respectively, allowing 5-min
incubations. Antibodies were visualised using the Vectastain Elite
ABC kit and chromogen 3,30-diaminobenzidine (DAB; Vector
Laboratories Ltd, Peterborough, UK) with incubations of 5 and
2min, respectively, and a 7s haematoxylin counterstain. Sections
were rapidly dehydrated through graded alcohols and then air-
dried for 5min. RNase inhibitor (Roche Diagnostics Ltd, Burgess
Hill, UK) was used at a concentration of 0.5Uml
 1 in all solutions.
Microdissection was performed using the PALM Microbeam
(PALM Microlaser Technologies GmbH, Bernried, Germany) using
the ‘close-cut autoLPC’ function. Capture buffer consisted of 0.5%
Igepal (Sigma-Aldrich, Poole, UK) in HPLC water with RNase
inhibitor. A total of 100–500 cells were captured from each section
and cells from two adjacent sections were pooled.
RNA extraction and amplification
The Picopure RNA extraction kit (Molecular Devices Ltd,
Wokingham, UK) was used according to the manufacturer’s
protocol. RNA was amplified through two rounds using the
ExpressArt Trinucleotide Amplification Nano Kit for degraded
RNA (Amp Tec GmbH, Hamburg, Germany). Amplified RNA
quality was assessed using the Agilent 2100 Bioanalyser (Agilent
Technologies UK Ltd, South Queensferry, UK).
Gene expression profiling and analysis
The Cancer Research UK Human Whole Genome-wide cDNA
Array v1.0.0 (32K) (http://www.crukdmf.icr.ac.uk) was used as
described earlier (Shepherd et al, 2008) and further information is
given in Supplementary Information. Data were normalised and
filtered to generate lists of genes with minimum 1.4-fold change in
expression in at least three of five samples. The functional
significance of differentially expressed genes was analysed using
the ‘Database for Annotation Visualization and Integrated
Discovery’ (DAVID) (http://david.abcc.ncifcrf.gov).
Semiquantitative PCR
Amplified RNA was reverse transcribed using Superscript II (Invitro-
gen Ltd, Paisley, UK). Primer sequences and cycling conditions are
provided in Supplementary Information. Following two rounds of
PCR, products were resolved on a 3% agarose gel and detected under a
UV transilluminator (BioDoc-It system; UVP, Cambridge, UK).
Immunofluorescence and immunohistochemistry
Paraffin-embedded sections were microwaved in antigen-unmask-
ing solution (Vector Laboratories) for 30min. Antibodies used are
listed in Supplementary Table S1. Immunofluorescent labelling was
carried out as described earlier (Alam et al, 2004). Immunohisto-
chemical staining of TMA cores was detected using the Advance
HRP kit and Liquid DABþ substrate chromogen system (Dako,
Ely, UK). Stained cores were reviewed by a pathologist. c-Cbl
staining was scored on a scale of increasing intensity (1–3) and
TEAD1 by increasing intensity (0–3) and as diffuse (in all tumour
cells) or focal (localised to small groups of tumour cells).
Statistical analyses for survival
Survival was measured using the dates of death from any cause and
death from prostate cancer. Patients were censored on their date of
last follow-up if no death had been recorded. Lifetables were generated
using the models of Kaplan and Meier. Differences between groups
were examined using the log-rank test. Univariate and multivariate
Cox regression analysis was performed using stepwise methods, a
P-value of 0.05 was used as a threshold for inclusion in the model.
Cell culture
The RWPE1 cell line was derived from benign prostate and PC3
from a prostate cancer bone metastasis (both ATCC, LGC
Standards, Teddington, UK). PC3 cells were cultured in F-12
Ham medium (Sigma-Aldrich) with 10% FCS (PAA Laboratories,
Yeovil, UK) and L-glutamine (Invitrogen). RWPE1 cells were
cultured in keratinocyte serum-free medium (KSFM) supplemen-
ted with bovine pituitary extract (25mg), human recombi-
nant epidermal growth factor (EGF) (2.5mg) and L-glutamine
(Invitrogen). Supplemented KSFM is referred to as bKSFM.
siRNA transfections
Pre-designed siRNA oligonucleotide duplexes for TEAD1 and c-Cbl
were purchased from Qiagen (Crawley, UK) and ON-TARGETplus
non-targeting siRNA no. 2 from Dharmacon (Thermo Scientific,
Cramlington, UK). Mock controls were included. Reverse transfec-
tions were performed by mixing suspended cells with the siRNA
oligonucleotides, Optimem I (Invitrogen) and Hiperfect (Qiagen),
before plating. Final siRNA oligonucleotide concentrations were
5n M (RWPE1) and 10nM (PC3).
MTS proliferation assays
Reverse-transfected cells were plated into 96-well plates or 6cm
dishes. At each time point, proliferation was assessed using the
Cell Titre 96 Aqueous One MTS assay (Promega, Southampton,
UK). Plates were read using a BioTek ELx800 plate reader at
490nm. Dishes were incubated for 72h and protein extracted for
knockdown verification. A one-way ANOVA with a Dunnett’s
multiple comparison test was performed in GraphPad Prism
Version 5.01 (GraphPad Software Inc.).
3D culture in matrigel
Twenty-four hours after reverse transfection, RWPE1 cells were
resuspended in bKSFM containing 2% Matrigel (BD Biosciences,
Oxford, UK) and seeded into Matrigel-coated eight-well chamber
slides (Nunc, VWR, Lutterworth, UK) (Debnath et al, 2003).
Duplicate dishes were incubated for 120h (corresponding to day 4
o ft h em a t r i g e la s s a y )b e f o r ep r o t e i ne x t r a c t i o n .A c i n if o r m e db yd a y
4 were scored and photographed under phase-contrast microscopy.
The numbers of organised acini and disorganised aggregates were
recorded for five fields of view. The number of disorganised
aggregates was expressed as a percentage of the total number of
structures and referred to as the percentage failure of acini formation.
Western blotting
Protein was extracted using mammalian protein extraction reagent
(Pierce, Thermo Scientific, Cramlington, UK) supplemented with
EDTA and protease inhibitor cocktail (Pierce). Lysates were
resolved on a 4–12% Bis–Tris Nupage gel (Invitrogen). Antibodies
were used as follows: TEAD1 (1:850), c-Cbl (1:1000), GAPDH
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s(Chemicon, Chandlers Ford, UK) 1:10000 and ECL peroxidase
secondary antibody (GE Healthcare, Amersham, UK) (1:5000).
RESULTS
Expression profiling of microdissected basal and luminal
cells identifies new markers for both populations
Basal and luminal cells were laser captured as illustrated in
Figure 1A. Two rounds of RNA amplification yielded 24–38mgo f
RNA with fragment sizes p1500bp. Microarray hybridisations were
performed for each of the five basal and luminal samples, hybridising
each against universal reference cDNA. Hierarchical clustering of the
gene set (Figure 1A) showed a clear segregation of basal and luminal
samples. A 1.4-fold cutoff relative to reference cDNA was applied
for all differentially expressed genes, yielding basal and luminal lists
of 112 and 267 genes, respectively. Basal/luminal or luminal/basal
fold-change ratios were calculated to directly compare the two
populations (Supplementary Tables S2a and S2b). K14 was over-
expressed in the basal population, confirming positive cell separa-
tion. A number of differentially expressed genes were selected for
verification of the microarray data by semiquantitative PCR
(Figure 1B). Luminal expression of SNAP25 was confirmed in three
out of three patients and basal expression of TEAD1 was confirmed
in two out of three patients. Basal expression of integrin aVw a s
confirmed in just one out of three patients and c-Cbl failed to
generate any product. Owing to the varying success of the PCR, due,
most likely, to the poor quality of the starting RNA, all further
localisation confirmation was carried out using antibody staining.
To identify differences in key biological processes between basal
and luminal cells, the web-based ontology program DAVID was
used. This program categorises genes based on their biological or
molecular function and assigns a P-value to each category. Filtering
on a P-value less than or equal to 0.05 returned 14 basal cell
categories and 23 luminal categories (Supplementary Table S3).
Immunofluorescence confirms the localisation of selected
markers
Commercially available antibodies were used to confirm the protein
localisation of a selection of novel markers in benign and malignant
prostate tissue by immunofluorescence. The selection included
genes identified as basal (ITGAV, TEAD1, c-Cbl and IL6)a n d
luminal (SPRY1 and SNAP25). Double labelling with either K14 or
K8 was used to confirm basal or luminal localisation of staining
within benign prostate tissue. In agreement with the expression
profiling data, TEAD1, c-Cbl and integrin aV were expressed in the
basal layer and SNAP25 in the luminal layer (Figure 2A). We were
unable to detect staining for IL6 or SPRY1. TEAD1 staining was
nuclear in all cells within the basal layer, whereas c-Cbl was strongly
cytoplasmic in the basal layer, with weak luminal staining. Integrin
aV was found in subsets of cells within the basal layer, and clusters
of integrin aV-positive cells were either K14 positive or negative.
The SNAP25 antibody detected luminal cells, with a vesicular
staining pattern. The same antibodies were also used on a small
selection of prostate tumour samples. Although expression of
SNAP25 and integrin aV could be detected in the tumours, integrin
aV labelling was often weak, and results for SNAP25 were
inconsistent between samples. As c-Cbl and TEAD1 staining was
consistently high, these proteins were chosen for further study. c-
Cbl was expressed in the cytoplasm of epithelial tumour cells,
whereas TEAD1 was confined to the nuclei (Figure 2A).
TEAD1 and c-Cbl are independent prognostic factors of
prostate cancer
To determine the clinical significance of TEAD1 and c-Cbl
expression in prostate tumours, TMAs were stained for the two
markers. Staining and patient data for positive cores are given in
Table 1, with examples of typical staining patterns in Figure 2B. As
shown by immunofluorescent staining, TEAD1 was localised to
Luminal Basal
Sample
1234514325
1B 4B 4L 2B 2L 1L
SNAP25
TEAD1
ITGAV
GAPDH
ab
ce
d
Figure 1 Laser-capture microdissection pressure catapulting (LMPC)
and expression profiling of basal and luminal prostate epithelial cells. (A)
Snap-frozen BPH tissue was rapid immunostained for basal cell marker K14,
with nuclei counter stained with haematoxylin (a). Basal and luminal
epithelial cells were laser captured sequentially; luminal cells were selected
(b), then captured (c), followed by selection (d) and capture (e) of K14-
positive basal cells. Extracted RNA from five patients was used for
expression profiling by cDNA microarray. Differentially expressed genes
were identified through ANOVA (P¼0.05). Genes were entered into
hierarchical cluster analysis represented here by a dendrogram. (B)
Semiquantitative RT–PCR of amplified RNA from three patient samples
(1, 2 and 4) confirming differential basal (B) and luminal (L) expression of
SNAP25, TEAD1 and integrin aV. Luminal expression of SNAP25 was
confirmed in three out of three patients; basal expression of TEAD1 was
confirmed in two out of three patients and basal expression of integrin aV
was confirmed in one out of three patients.
TEAD1 and c-Cbl as prognostic markers in prostate cancer
JF Knight et al
1851
British Journal of Cancer (2008) 99(11), 1849–1858 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sbasal cell nuclei, whereas that for c-Cbl was cytoplasmic. In some
strongly stained regions of the TMA, c-Cbl also appeared to be
perinuclear (Figure 2B C2). The scoring systems are described in the
Materials and Methods. Kaplan–Meier survival curves for TEAD1
and c-Cbl, representing deaths from all causes and prostate cancer-
specific deaths, are shown in Figure 3. Staining distribution (focal or
diffuse) and staining intensity for TEAD1 were considered as
separate parameters. Diffuse staining was found to correlate with a
poorer patient prognosis than focal (P¼0.0092) (Figure 3A).
However, this was not a significant factor in multivariate analysis
because of a strong correlation with Gleason score, with diffuse
TEAD1 staining found in predominately high Gleason cancers
(Table 1). Staining intensity for TEAD1 showed a clear overlap in
patient survival for groups 1 and 2, and patients with the highest
intensity staining (group 3) had a highly significant reduced survival
rate (P¼0.0009) (Figure 3B). For both parameters, these differences
are most striking in the prostate cancer-specific survival data.
c-Cbl staining was scored solely by intensity (scores 1–3).
Survival data showed a clear divergence of intensity groups 1 and 2
at 7.5 years post-diagnosis, with an increased mortality rate for
group 2 (Figure 3C). Group 3 patients had a particularly poor
prognosis with a 50% survival rate of only 6 years compared with
14 years for group 1 (P¼0.0106).
In Cox regression multivariate analysis, TEAD1 staining
intensity scores were significantly associated with increased
mortality, with a hazard ratio of 1.56 (95% CI 1.02–2.37;
P¼0.037) (Table 2).
Similarly, c-Cbl was found to be a highly significant independent
predictor of survival (P¼0.0005) with a hazard ratio of 1.99 (95%
CI 1.35–2.92). One factor significant in the univariate analysis,
although not in the multivariate analysis, was age.
Interestingly, of the 10 patients presenting with TEAD1 level 3,
only four had level-3 c-Cbl, and there does not therefore appear to
be a direct correlation between the two markers. This suggests that
while high levels of either TEAD1 or c-Cbl are indicative of equally
poor prognosis, they may identify somewhat different tumour
types, supporting the observation that prostate cancer is a truly
heterogeneous disease.
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Figure 2 Immunofluorescent and immunohistochemical labelling of benign and cancerous prostate tissue for basal and luminal cell markers. (A) Benign
tissue: nuclear TEAD1 labelling (green) was found in K14-positive basal cells (red). Note turquoise double-stained TEAD1-positive nuclei. Cytoplasmic
staining for c-Cbl (green) was strong in basal cells and weak in luminal cells as shown by co-labelling with luminal marker K8 (red). SNAP25 (green) staining
was luminal in a speckled vesicle-like pattern. Integrin aV (green) was restricted to basal cells, either co-localised to K14 (red) or alone. In prostate tumours,
the expression of TEAD1 and c-Cbl was strong despite the absence of a basal layer. Occasional areas of tumour tissue labelled intensely for SNAP25.
Integrin aV expression in tumour tissue was extremely weak. Original magnification  63 to  100. (B) Scoring systems were derived for both TEAD1 and
c-Cbl. TEAD1 scored first as focal (F) or diffuse (D) followed by a score for intensity (1¼low to 3¼high). Tumour cores lacking TEAD1 expression were
scored as negative (neg). Scoring for c-Cbl was based on intensity alone (C1¼low to C 3¼high). Original magnification  40.
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sKnockdown of TEAD1 or c-Cbl reduces proliferation in
PC3 cells
To investigate whether TEAD1 or c-Cbl has a role in proliferation,
two well-established prostate cell lines were transfected with siRNA
oligonucleotides targeting each gene. Knockdown was confirmed
by western blotting and the effect on proliferation quantitated by
MTS assays carried out over a 96-h time course (Figure 4A).
Although the proliferation of RWPE1 cells was not affected by
knockdown of either TEAD1 or c-Cbl, the proliferation of PC3 cells
was significantly reduced. Data were normalised to proliferation of
cells transfected with non-targeting siRNA. Normalisation to
proliferation of mock-transfected cells yielded similar results.
Knockdown of TEAD1 or c-Cbl affects acinar formation in
3D culture
RWPE1 cells form spherically polarised acini, representative of the
glandular structure of the prostate when cultured on matrigel
(Webber et al, 1997). Cells were seeded in matrigel 24h after
transfection with TEAD1 or c-Cbl siRNA. After 4 days, acinar-like
spherical structures with a well-defined border, often with less-
dense cells in the centre, were formed (Figure 4Ba). Disorganised
clusters were defined as aggregates of four or more cells that failed
to form spherically polarised acini (Figure 4Bb and c). At day 4, the
percentage failure of acini formation was calculated. The mean
results of three independent experiments are shown in Figure 4B.
TEAD1 knockdown significantly disrupted the number of spheri-
cally organised structures in comparison to the non-targeting
control transfections, with an increased occurrence of disorganised
clusters (T1_1¼P0.006, T1_3¼P0.009). Similarly, knockdown of
c-Cbl also significantly reduced acini formation (cbl_8¼P0.08,
cbl_9¼P0.003). These results are comparable with those of
Kawano et al (2006), who found a 30% failure of acinar formation
in response to the knockdown of the Wnt signalling pathway
component Dickkopf-3 (DKK3).
DISCUSSION
Deregulation of proliferation and differentiation of prostate
epithelial cells are predicted to underlie the development and
progression of prostate cancers. As these processes are not well
understood, it is not currently possible to predict patient outcome
accurately. To identify key molecular factors involved in these
processes, we have profiled gene expression associated with the
basal and luminal epithelial cell layers. Genes expressed in basal
cells are involved in maintaining a proliferative undifferentiated
phenotype and promote cell survival. Therefore, we hypothesised
that genes with their expression normally restricted to the basal
layer play a key role in the progression of prostate malignancy. In
this study, we determined the prognostic significance in prostate
cancer of two novel markers of benign prostate basal cells.
Approaches to isolating different epithelial cell populations from
the prostate have included lengthy processing and cell culture.
This is expected to alter patterns of gene expression compared
with cells in vivo. Therefore, we used laser-capture microdissection
(Espina et al, 2007) combined with immunostaining for cellular
recognition. As standard immunohistochemistry protocols lower
RNA quality (Fend et al, 1999), we optimised a protocol to
Table 1 Summary of patient details for c-Cbl and TEAD1 staining
Patient summary
c-Cbl TEAD1
Total cancers 101 96
Total benign 90 95
Age range (years) 43–84 43–84
Median age (years) 64 66
Follow-up time (years) 0.4–16.6 1.25–16.6
Median follow-up (years) 6.75 6.85
AJCC stage
I2 2
II 36 34
III 24 24
IV LA T4 or N1 16 16
IV metastatic 23 20
Gleason grade
Well (2–4) 17 18
Moderate (5–7) 54 50
Poor (8–10) 29 26
Missing 1 2
Staining summary
Total positive Metastasis positive Gleasono7 GleasonX7
CBL 1 32 8 (25%) 22 (71%) 9 (29%)
CBL 2 44 9 (21%) 27 (61%) 17 (39%)
CBL 3 25 6 (24%) 11 (44%) 14 (56%)
TEAD1 0 7 1 (14%) 6 (86%) 1 (14%)
TEAD1 1 30 6 (24%) 22 (75%) 7 (25%)
TEAD1 2 49 10 (20%) 21 (44%) 27 (56%)
TEAD1 3 10 3 (30%) 2 (20%) 8 (80%)
TEAD1 focal 53 14 (26.5%) 40 (75.5%) 12 (22.6%)
TEAD1 diffuse 36 18 (50%) 11 (30.6%) 24 (66.7%)
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profiling of the microdissected cells. The 1.46-fold elevation of
K14 expression levels in basal cells is modest considering that
staining patterns show basal specificity. However, a lack of direct
concordance between relative mRNA and protein levels in prostate
tissue has been demonstrated earlier (Pascal et al, 2008).
Gene ontology analysis defined the functional categories
upregulated in the two cellular populations. Luminal cells
expressed negative regulators of the cell cycle, including the
cyclin-dependent kinase inhibitors p21
CIP1/WAF1 (CDKN1A) and
p27
KIP (CDKN1B), the latter having earlier been localised to
prostate luminal cells (Harper et al, 1993; Fernandez et al, 1999),
and the tumour suppressor genes NBL1 (Enomoto et al, 1994),
NDRG1 (Daly-Burns et al, 2007) and PHB, which are down-
regulated in prostate cancer cells (Gamble et al, 2007). In keeping
with the known interaction between the AR and calmodulin
(Cifuentes et al, 2004), a further luminal functional category
included several proteins related to calmodulin binding. Present in
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Figure 3 Kaplan–Meier curves. Kaplan–Meier analysis of overall and disease-specific survival for prostate cancers stained for TEAD1 (A and B) and c-Cbl
(C). TEAD1 staining scored for either distribution (A) or intensity (B).
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Although SNAP25 has not earlier been described in prostate, it
has an established role in membrane trafficking and exocytosis for
hormone secretion in other tissues, such as the pancreas (Sadoul
et al, 1995).
The basal cell profile was consistent with a proliferative
phenotype, with expression of CXCL1, NBS1 and RPA, all of which
encode proteins shown earlier to promote proliferation (Chiang
et al, 2003; Li et al, 2004; Givalos et al, 2007). The expression of aV
integrin has earlier been described in metastatic prostate cancer
(McCabe et al, 2007) but not in benign prostate cells, where it may
have a role in adhesion to the basement membrane.
The protein localisation of two highly ranking genes in the basal
list, protooncogene c-Cbl and the transcription factor TEAD1,
confirmed them as basal cell markers not described earlier in
prostate. Furthermore, an increased staining intensity for both
c-Cbl and TEAD1 was observed in prostate cancer samples on a
TMA. Significantly, multivariate analysis confirmed both as
Table 2 Analysis of overall survival
Variable Group N d.f. P-value Hazard ratio Lower 95% confidence interval Upper 95% confidence interval
Univariate analysis
c-Cbl staining intensity 1 32 1 1
2 44 1 0.1049 1.7123 0.8939 3.2802
3 25 1 0.0017 3.2627 1.5569 6.8375
c-Cbl staining intensity Continuous 101 1 0.0019 1.8090 1.2448 2.6290
Age Continuous 101 1 0.0002 1.0664 1.0304 1.1037
PSA Continuous 41 1 0.0009 1.0044 1.0018 1.0070
Gleason score Continuous 100 1 0.0000 1.3670 1.2048 1.5510
Gleason score Gleasono76 01 1
GleasonX7 40 1 0.0000 4.1135 2.3917 7.0748
AJCC stage 1 2 1 0.2349 3.5565 0.4384 28.8493
23 6 1 1
3 24 1 0.0067 3.2883 1.3912 7.7726
4 M0 16 1 0.0005 4.7513 1.9644 11.4919
4 M1 23 1 0.0000 9.0662 3.9812 20.6460
Multivariate analysis
c-Cbl staining intensity Continuous 100 1 0.0005 1.9895 1.3513 2.9291
Gleason score Gleasono76 0 1
GleasonX7 40 1 0.0001 3.5851 1.9242 6.6795
AJCC stage 1 2 1 0.1715 4.3962 0.5265 36.7064
23 6 1
3 23 1 0.4293 1.4602 0.5711 3.7333
4 M0 16 1 0.0039 3.7042 1.5206 9.0236
4 M1 23 1 0.0000 8.6743 3.6294 20.7316
Variables not in the model
Age Continuous 100 1 0.3219
Univariate analysis
TEAD1 staining intensity 0 7 1 1
1 30 1 0.2966 1.9435 0.5580 6.7693
2 49 1 0.1981 2.1990 0.6624 7.3009
3 10 1 0.0033 7.4536 1.9482 28.5157
TEAD1 staining intensity Continuous 96 1 0.0065 1.7102 1.1621 2.5169
Age Continuous 96 1 0.0004 1.0673 1.0293 1.1066
PSA Continuous 38 1 0.0045 1.0048 1.0015 1.0081
Gleason score Continuous 94 1 0.0000 1.3415 1.1784 1.5272
Gleason score Gleasono75 71 1
GleasonX7 37 1 0.0000 4.2115 2.3747 7.4688
AJCC stage 1 2 1 0.1672 4.4911 0.5331 37.8367
23 4 1 1
3 24 1 0.0022 4.4203 1.7105 11.4227
4 M0 16 1 0.0005 5.7426 2.1493 15.3436
4 M1 20 1 0.0000 12.0225 4.7692 30.3073
Multivariate analysis
TEAD1 staining intensity Continuous 94 1 0.0365 1.5615 1.0284 2.3708
Gleason score Gleasono75 71 1
GleasonX7 37 1 0.0011 3.0741 1.5632 6.0455
AJCC stage 1 2 1 0.0536 8.5127 0.9677 74.8866
23 4 1 1
3 23 1 0.0840 2.4744 0.8855 6.9144
4 M0 16 1 0.0035 4.4048 1.6275 11.9214
4 M1 19 1 0.0000 12.6098 4.7733 33.3118
Variables not in the model
Age Continuous 94 1 0.0646
PSA¼prostate-specific antigen. Statistical tests were performed as described in Materials and Methods. For statistical analysis, the AJCC stage 4 tumours were divided into
categories without (M0) or with (M1) distant metastases.
TEAD1 and c-Cbl as prognostic markers in prostate cancer
JF Knight et al
1855
British Journal of Cancer (2008) 99(11), 1849–1858 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sprognostic markers. Further study is now needed to investigate
their possible clinical applications in the future. There is an urgent
need for new predictive markers that distinguish the most
aggressive prostate cancers at an early stage. Currently under
investigation for its potential as a prognostic marker is the non-
coding RNA PCA3 (Hessels et al, 2003). Although PCA3 has been
proposed as an alternative to PSA for prostate cancer detection, its
actual prognostic value is uncertain (van Gils et al, 2008). Likewise,
although a-methylacyl CoA racemase (AMACR) staining is used
diagnostically, it is not used to predict patient outcome (Luo et al,
2002). One recently discovered DNA biomarker that may provide
prognostic information is the fusion between the gene TMPRSS2
and the ETS family genes such as ERG (Tomlins et al, 2005). In
particular, duplication of the TMPRSS2–ERG fusion has been
shown to identify aggressive tumours in patients whose prostate
cancers had been assigned only intermediate Gleason scores
(Attard et al, 2008). As staining intensities of both TEAD1 and
c-Cbl also predict survival independently of Gleason score, they
may prove also to be of significant prognostic value.
c-Cbl belongs to a family of E3 ubiquitin ligases (Swaminathan
and Tsygankov, 2006). It binds to and ubiquitinates a range of
receptor tyrosine kinases including EGFR (de Melker et al, 2001)
and MET (hepatocyte growth factor receptor) (Peschard et al,
2001), both of which are localised to the basal layer and have
reported roles in prostate proliferation and differentiation
(Ibrahim et al, 1993; Pisters et al, 1995; Knudsen and Edlund,
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s2004; Schlomm et al, 2007). Receptor tyrosine kinases bound to
c-Cbl are targeted to the endosomal compartment from where
they are either trafficked to lysosomes for degradation or
recycled back to the plasma membrane (Thien and Langdon,
2001). c-Cbl is, therefore, normally regarded as a negative
regulator of proliferation. Interestingly, however, knockdown of
c-Cbl in PC3 cells decreased proliferation. Importantly, c-Cbl also
functions as an adaptor protein in signal transduction, for example
downstream of integrins in which c-Cbl has been shown to interact
with c-Src (Edick et al, 2007). Further investigation is needed to
establish the role of c-Cbl in regulating prostate cancer cell
proliferation.
The TEAD family of transcription factors, of which TEAD1 is the
best characterised, regulate growth and differentiation in many
tissues. This is exemplified by an important role for TEAD1 in
embryonic development (Sawada et al, 2008; Zhang et al, 2008).
TEAD1 binds several co-activators to stimulate the transcription of
target genes (Gupta et al, 1997, 2001). Importantly, Yes-associated
protein (YAP) is a TEAD1 co-activator localised to basal cell nuclei
in normal prostate and overexpressed in prostate cancer (Zhao
et al, 2007). TEAD1–YAP complexes promote the transcription of
proliferative genes upon translocation of YAP to the nucleus, a
process regulated by the Hippo pathway, which controls cell-
contact inhibition of growth (Bandura and Edgar, 2008; Wu et al,
2008). As knockdown of TEAD1 led to a reduced proliferation in
PC3 cells, it is possible that an increased expression of both TEAD1
and YAP could stimulate proliferation in prostate cancer.
The fact that knockdown of either TEAD1 or c-Cbl decreases the
proliferation of PC3, but not RWPE1, is very interesting. This may
reflect the different origins of the cell lines, RWPE1 having been
immortalised from benign cells, whereas PC3 is of prostate cancer
origin, representative of a highly aggressive, metastatic disease. As
both TEAD1 and c-Cbl are highly expressed in aggressive prostate
cancers, it could be possible that these aggressive cancers, and
hence PC3, are dependent on these genes, directly or indirectly, for
their proliferative capacity. Alternatively, RWPE1 proliferation
may have been unaffected by TEAD1 or c-Cbl knockdown due to
the immortalisation of this cell line with HPV18, which leads to the
inactivation of p53 and Rb and, therefore, artificially high levels of
proliferation. As a consequence of this, RWPE1 may have the
ability to proliferate independently of TEAD1 or c-Cbl.
Although knockdown of TEAD1 or c-Cbl in RWPE1 did not affect
proliferation in 2D culture, the ability of these cells to form acini in
an established 3D assay (Bello-DeOcampo et al, 2001; Kawano et al,
2006) was compromised. These data suggest that TEAD1 and c-Cbl
could have roles in regulating prostate epithelial cell differentiation
and may have additional functions in epithelial morphogenesis,
such as regulating adhesion to the basement membrane and
associated signalling. Earlier studies have implicated a role for
TEAD1 in the differentiation of keratinocytes (Takahashi et al,1 9 9 5 )
and skeletal muscle cells (Maeda et al,2 0 0 2 ) ,a n dar o l ef o rc - C b li n
maintaining an organised epithelium has been suggested earlier
(Fournier et al, 2000). These preliminary functional studies clearly
warrant further investigation into the roles of c-Cbl and TEAD1 in
growth and differentiation in the prostate.
I ns u m m a r y ,w eh a v eu s e dan o v e la p p r o a c ht oi d e n t i f yt w ob a s a l
cell markers with high prognostic significance for prostate cancer.
Interestingly, our preliminary functional study using well-established
prostate cell lines has suggested a role for both genes in cellular
proliferation and differentiation in the prostate, the two processes
that are aberrantly regulated in cancer. Further study of TEAD1, c-Cbl
and other basal markers may allow us to get an insight into the key
molecular pathways that become disrupted in prostate malignancy.
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